Market Research Logo

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Review, H2 2016’, provides in depth analysis on Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted pipeline therapeutics.

The report provides comprehensive information on the Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
  • The report reviews Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) Overview
Therapeutics Development
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Products under Development by Stage of Development
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Products under Development by Therapy Area
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Products under Development by Indication
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Products under Development by Companies
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Products under Development by Universities/Institutes
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Companies Involved in Therapeutics Development
Astellas Pharma Inc.
BerGenBio AS
Betta Pharmaceuticals Co. Ltd.
Chugai Pharmaceutical Co., Ltd.
Exelixis, Inc.
HEC Pharm Co., Ltd.
Ignyta, Inc.
Les Laboratoires Servier SAS
Mirati Therapeutics Inc.
NeoPharm Co., Ltd.
Oribase Pharma
SignalChem Lifesciences Corp
Tolero Pharmaceuticals, Inc.
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Drug Profiles
BGB-10C9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGB-324 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BPI-9016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cabozantinib s-malate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CH-5451098 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-053 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-413 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gilteritinib fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glesatinib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MGCD-516 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 2 to Inhibit AXL Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody 3 to Inhibit AXL Kinase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NPS-1034 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Q-701 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Thrombosis and Non-Small Cell Lung Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RXDX-106 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
S-49076 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SGI-7079 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SLC-0211 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AXL, FLT3 and ARK5 for Solid Tumor and Hematological Tumor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit AXL, FLT3 and NTRK for Solid Tumors and Blood Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TP-0903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Dormant Projects
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Discontinued Products
Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 2.7.10.1) - Featured News & Press Releases
Jun 07, 2016: BerGenBio Reports First-in-Patient Phase 1 Data for BGB324 in Patients with Myeloid Malignancies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Jun 05, 2016: Mirati Therapeutics Provides Update On Glesatinib Program
Jun 05, 2016: Exelixis and its partner Ipsen announce phase 3 trial results of CABOMETYX (cabozantinib) tablets demonstrating significant overall survival benefit for previously treated patients with advanced renal cell carcinoma presented at ASCO
Jun 05, 2016: Mirati Therapeutics Provides Update On Sitravatinib Program
May 23, 2016: Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progression-free survival versus sunitinib in previously untreated advanced renal cell carcinoma
May 19, 2016: Mirati Therapeutics To Present Abstracts On glesatinib At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting
May 19, 2016: Mirati Therapeutics To Present Abstracts On sitravatinib (MGCD516) At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting
May 19, 2016: Astellas Oncology Announces Data on gilteritinib to be Presented at 2016 ASCO Annual Meeting
Apr 26, 2016: Diplomat to Dispense CABOMETYX (cabozantinib) Tablets for the Treatment of Advanced Renal Cell Carcinoma
Apr 25, 2016: Exelixis Announces FDA Approval of CABOMETYX (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
Apr 20, 2016: Exelixis Announces Presentation On Cabozantinib At 2016 ASCO Annual Meeting
Apr 18, 2016: BerGenBio presents new data demonstrating that BGB324 enhances checkpoint inhibitor blockade
Apr 18, 2016: Tolero Pharmaceuticals Presents Data Demonstrating AXL Inhibition Leads to a Reversal of a Mesenchymal Phenotype Sensitizing Cancer Cells to Targeted Agents and Immuno-Oncology Therapies
Apr 12, 2016: Rigel Announces Presentation on preclinical research project MerTK at Upcoming American Association of Cancer Research (AACR) Conference
Apr 12, 2016: Tolero Pharmaceuticals to Present Update on TP-0903 at the AACR Annual Meeting 2016
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Number of Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Pipeline by Astellas Pharma Inc., H2 2016
Pipeline by BerGenBio AS, H2 2016
Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
Pipeline by Exelixis, Inc., H2 2016
Pipeline by HEC Pharm Co., Ltd., H2 2016
Pipeline by Ignyta, Inc., H2 2016
Pipeline by Les Laboratoires Servier SAS, H2 2016
Pipeline by Mirati Therapeutics Inc., H2 2016
Pipeline by NeoPharm Co., Ltd., H2 2016
Pipeline by Oribase Pharma, H2 2016
Pipeline by SignalChem Lifesciences Corp, H2 2016
Pipeline by Tolero Pharmaceuticals, Inc., H2 2016
Dormant Projects, H2 2016
Dormant Projects (Contd..1), H2 2016
Discontinued Products, H2 2016
List of Figures
Number of Products under Development for, H2 2016
Number of Products under Development by Therapy Area, H2 2016
Number of Products under Development by Top 10 Indication, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy/Combination Products, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Type, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report